Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akari Therapeutics (AKTX) Long-Term Investments (2015 - 2022)

Akari Therapeutics recorded quarterly Long-Term Investments of $20339.0 in Q4 2022, little changed quarter-over-quarter from $20339.0 in Q4 2021, and little changed year-over-year from $20339.0 in Q4 2021.

Akari Therapeutics' Long-Term Investments history runs 8 years deep, the most recent figure standing at $20339.0 for Q4 2022.

  • In Q4 2022, Long-Term Investments changed 0.0% year-over-year to $20339.0; the TTM figure through Dec 2022 stood at $20339.0 (changed 0.0% YoY), while the FY2022 annual figure was $20339.0, changed 0.0% from the prior year.
  • Long-Term Investments came in at $20339.0 for Q4 2022 at Akari Therapeutics, roughly flat from $20339.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $20339.0 in Q4 2018 to a low of $20339.0 in Q4 2018.
  • A 5-year average of $20339.0 and a median of $20339.0 in 2018 frame the typical range for Long-Term Investments.
  • On a YoY basis, Long-Term Investments climbed as much as 0.0% in 2018 and fell as far as 0.0% in 2018.
  • Akari Therapeutics' Long-Term Investments stood at $20339.0 in 2018, then changed by 0.0% to $20339.0 in 2019, then changed by 0.0% to $20339.0 in 2020, then changed by 0.0% to $20339.0 in 2021, then changed by 0.0% to $20339.0 in 2022.
  • According to Business Quant data, Long-Term Investments over the past three periods registered $20339.0, $20339.0, and $20339.0 for Q4 2022, Q4 2021, and Q4 2020 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 505,194.89
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 5.75 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 9.79 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 22.17 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2022 20,339.00
Dec 31, 2021 20,339.00
Dec 31, 2020 20,339.00
Dec 31, 2019 20,339.00
Dec 31, 2018 20,339.00
Dec 31, 2017 20,339.00
Dec 31, 2016 20,339.00
Dec 31, 2015 20,339.00